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Summary. Cisplatin, raceme-diaqua[1,2-bis(4-fluoro- 
phenyl)ethylenediamine]platinum(II) sulfate (compound 
I), meso-diaqua[ 1,2-bis(4-fluorophenyl)ethylenediamine]- 
platinum(II) sulfate (compound II), and meso-diaqua[1,2- 
bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]plati- 
num(II) sulfate (compound III) were compared with regard 
to their effect on the MCF-7 breast cancer cell line in vitro. 
At equimolar concentrations (5 gM), cisplatin, compound 
I, and compound II were equiactive after 231 h drug expo- 
sure, whereas compound III was ineffective. Although 
compounds I and II showed markedly greater inactivation 
than did cisplatin after 6 h incubation with culture medium, 
compound I (but not compound II) exhibited antitumor 
activity equivalent to that of cisplatin when cells were 
exposed to the drugs for 6 h. Platinum measurements by 
neutron-activation analysis revealed that compound I was 
selectively and rapidly accumulated by MCF-7 cells, re- 
suiting in a high degree of DNA platination within the first 
few hours of drug exposure. However, when the drug-ex- 
posure period was long enough, platinum enrichment was 
not reflected in an overall difference in the cytotoxicity of 
compound I vs cisplatin. Nevertheless, compound I should 
be superior to cisplatin in vivo, provided that effective 
plasma levels can be maintained for about 6 h. 
Introduction 
Cisplatin is the primary building block in regimens used to 
treat human testicular carcinoma, and it produces high 
response rates in patients uffering from head and neck, 
ovarian, bladder, and small-cell lung cancers. However, 
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the clinical effectiveness of cisplatin is greatly compro- 
mised by its severe undesirable side effects and by the 
complete refractoriness of some tumors to cisplatin treat- 
ment. These factors have stimulated the synthesis and eval- 
uationof many new platinum complexes [13, 19] based on 
the desire to find compounds that produce reduced toxicity 
and exhibit a broader spectrum of activity, particularly in 
clinical diseases in which cisplatin has not demonstrated a 
therapeutic effect (e.g., mammary and prostatic carci- 
nomas). 
Stereoisomeric (1,2-diphenylethylenediamine)plati- 
num(II) complexes have been reported to exert marked 
antileukemic activity [11, 20, 33]. Quite recently, our 
group has described iastereoisomeric ng-substituted 
(1,2-diphenylethylenediamine)platinum(II) complexes 
that have been highly effective against several rodent 
tumor models in vivo. Meso-configurated [1,2-bis(2,6- 
dichloro-4-hydroxyphenyl)ethylenediamine]platinum(II) 
complexes exhibit hormone-like properties and have been 
found to produce high response rates in the hormone-sensi- 
tive rodent tumor models MXT (M 3.2) mammary carcino- 
ma of the B6D2F1 mouse, DMBA-induced mammary car- 
cinoma of the Sprague-Dawley rat[ 14, 29], and Dunning R 
3327 and Noble prostatic carcinoma of the rat [27]. 
Diastereoisomeric diaqua[ 1,2-bis(4-fluorophenyl)ethy- 
lenediamine]-platinum(II) salts, which lack estrogenic ac- 
tivity, produce strong inhibition of the ovarian-dependent 
MXT (M 3.2) mammary carcinoma of the B6D2F1 mouse. 
In contrast to the racemic ompounds, the meso-configu- 
rated complexes are also active against the hormone-inde- 
pendent MXT (M 3.2)-OVEX mammary carcinoma of the 
B6D2F1 mouse [25]. Antitumor agents that effect estro- 
gen-receptor-positive and-negative breast cancers would 
be of enormous therapeutic value, since drugs of this type 
should delay (or perhaps prevent) the development of re- 
sistance to hormonal therapy caused by the proliferation of 
hormone-insensitive umor cell clones. 
Interestingly, the aforementioned ring-substituted 
diaqua(1,2-diphenylethylenediamine)platinum(II) salts are 
highly active against rodent breast cancer models, although 
such complexes are charged species. It is generally ac- 
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cepted that ionized compounds cannot diffuse freely across 
membrane barriers [22]. Thus, the literature reporting 
on the antitumor activity of charged complexes i scanty 
[6, 7, 16]. 
Due to their unrealistically high sensitivity to cisplatin, 
murine mammary carcinomas have been suspected to be 
inappropriate models for testing of platinum analogues 
[30, 31], since it is well known that cisplatin is ineffective 
in the therapy of human breast cancer. Therefore, accord- 
ing to the new test strategy of the National Cancer Institute, 
human (breast) cancer models are preferable. 
In the present study, we laid the foundations for the 
further testing of these compounds on human mammary 
carcinomas implanted into nude mice, by determining the 
conditions for an optimal in vivo schedule. For this pur- 
pose, we compared the diastereoisomeric diaqua[ 1,2-bis(4- 
fluorophenyl)ethylenediamine]platinum(II) s lfates (com- 
pounds I and II) and meso-diaqua[1,2-bis(2,6-dichloro- 
4-hydroxyphenyl)ethylenediamine]platinum(II) sulfate 
(compound III) with cisplatin in terms of their stability in 
culture medium, their dose-dependent antitumor activity, 
the time required to obtain a cytocidal drug effect, the 
kinetics of platinum accumulation by the hormone-sensi- 
tive MCF-7 human breast cancer cell line [2, 3] and the 
extent of DNA platination. 
Materials and methods 
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Chemicals 
Reagents (A-grade purity) were obtained from Merck (Darmstadt, FRG). 
N-Hexamethylpararosaniline (crystal violet) and trypsin (1:250, v/v), 
were purchased from Serva (Heidelberg, FRG). N,N-Dimethylform- 
amide (DMF, spectrophotometric grade) was obtained from Aldrich 
(Steinheim, FRG). Guanidinium hydrochloride, dithioerythritol (DTE), 
and sodium pyruvate were supplied by Sigma (Mt~nchen, FRG). Bio-rad 
protein-assay d e-reagent concentrate was obtained from Bio-rad Labo- 
ratories (Mtinchen, FRG), and human serum albumin (HSA) was sup- 
plied by Behring (Marburg, FRG). Millipore-filtered water was used 
throughout the experiments. 
Cell culture 
The human MCF-7 breast cancer cell line [28] was obtained from the 
American Type Culture Collection (ATCC, Rockville, Md., USA). Cell- 
line banking and quality control was performed according to the seed 
stock concept reviewed by Hay [12]. The MCF-7 (ATCC number HTB 
22) cells were maintained in MEM Eagle's medium (Sigma, Mtinchen, 
FRG) containing L-glutamine, NaHCO3 (2.2 g/l), sodium pyruvate 
(110 mg/1), gentamycin (50 mg/1; Sebio, Walchsing, FRG), and 10% 
fetal calf serum (FCS; Gibco, Eggenheim, FRG) using 75-cm 2 culture 
flasks (Falcon Plastics 3023) in a water-saturated atmosphere (95% 
air/5% CO2) at 37 ~ C. The cells were serially passaged weekly following 
trypsinization using 0.05% trypsird0.02% ethylenediaminetetraacetic 
acid (EDTA; Boehringer, Mannheim, FRG). Mycoplasma contamination 
was routinely monitored, and only Mycoplasma-free cultures were used. 
Drugs 
Cisplatin (gold labet) was obtained from Aldrich (Steinheim, FRG). The 
structures of the diaqua(1,2-diphenylethylenediamine)platinum(II) sul- 
fates are shown in Fig. 1. Their synthesis as well as their chemical and 
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Fig. 1. Structures of the cisplatin analogues used in the chemosensitiv- 
ity and accumulation studies. Compound I: raceme-diaqua[1,2-bis(4- 
fluorophenyl)ethylenediamine]platinum(II) s lfate.Compound 1I: meso- 
diaqua[ 1,2-his(4- fluorophenyl)ethylenediamine]platinum(II) sulfate. 
Compound III: meso-diaqua[1,2-bis(2,6-dichloro-4-hydroxyphenyl)- 
ethylenediamine]platinum(II) sulfate 
(some) biological properties have been described elsewhere [14, 18, 24, 
25]. Despite the ionic nature of the diaqua(1,2-diphenylethylenedi- 
amine)platinum(II) sulfates, their water solubility is quite low because of 
the contribution of the large, hydrophobic neutral ligand. Therefore, for 
all platinum complexes, 10-raM stock solutions were prepared in DMF. 
After appropriate dilution of the stock solution, feed solutions were 
made. The drugs (i. e., the feed solutions) were added to the culture 
medium such that the final DMF concentration was 0.1% (v/v). 
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Chemosensitivity assay 
We have recently reported the principle and the applications of the 
kinetic crystal violet assay [2, 23]. In brief, cells were seeded 
(100 gl/well) in 96-well flat-bottomed microtitration plates (Falcon Plas- 
tics 3075). After 48 h (corresponding to an absorbance of approx. 0.2), 
the medium was carefully removed by suction and replaced by fresh 
medium (200 gl/well) containing drug (feed solutions were diluted 
1 : 1,000 with culture medium) or pure solvent. On each plate, 16 wells 
served as controls and 16 wells were used per drug concentration. After 
various periods of incubation, the culture medium was shaken off and the 
cells were fixed with 100 p.1 1% glutardialdehyde in phosphate-buffered 
saline (PBS) per well for 15 min. The fixative was replaced by 150 gt 
PBS/well and the plates were stored in the refrigerator (4~ C). At the end 
of the experiment, all trays were simultaneously stained with 0.02% 
aqueous crystal violet solution (100 gl/well) for 30 rain. Excess dye was 
removed by rinsing the trays with water for 15 rain. The stain bound by 
the cells was redissolved in70% ethanol (180 ~tl/well) during shaking of 
the microplates for about 3 h. Absorbance (a parameter proportional to 
cell mass) was measured at 578 nm using a Biotek 309 Autoreader 
(Tecnomara, Fernwald, FRG). Drug effects were expressed as corrected 
T/C values for each group (in percent) according to the equation 
T/Coorr = (T-C0)/(C~20) X 100, (1) 
where T represents he mean absorbance of the treated cells; C, the mean 
absorbance of the controls, and Co, the mean absorbance of the cells at 
time zero, when the drug was added. 
ampoules made of ultrapure quartz (Suprasil AN, Heraeus Quarz- 
schmelze GmbH, Hanau, FRG). The cleaning of the ampoules has been 
described elsewhere [17]. The sealed ampoules were irradiated together 
with quartz ampoules containing hexachloroplatinum(IV) acid as a stan- 
dard in the Forschungsreaktor Mtinchen at a thermal neutron flux of 
2x l ,013cm-2s -1 for 50 h. After irradiation and a decay time of 
2 -3  days, the ampoules were cleaned on the outside [17]. The gamma 
spectra of the samples and the standards were recorded [counting 
equipment: 130-cm 3 intrinsic coaxial Ge detector (2.1-keV resolution 
and 27% relative efficiency, both for the 1,332.50-keV gamma line of 
6~ main amplifier, Silena model 7611; ADC Silena model 7423 
UHS; memory buffer module, Silena 7329-16 K; personal computer, 
Silena AT/03/CO]. 
For evaluation of the gamma spectra, emulation software MMB3 was 
used. The ampouIes were positioned with their axes parallel to the 
detector surface at a distance of 4 -10 cm. 199Au was chosen as the 
reference nuclide for platinum [32]. The evaluation was based on the 
158.37-keV and on the 208.20-keV gamma lines of ~99Au. The detection 
limit for platinum lay between 1 ng (4-cm distance) and 2 ng (10-cm 
distance)/sample. 
Protein determination. Samples (50-200 mg cell suspension) were 
dried at 80 ~ C, and total protein was dissolved in 300 gl denaturation 
buffer (6 M guanidinium hydrochloride, 50 mu DTE, 0.5 M TRIS/HC1, 
pH 8.5). Protein was measured after appropriate dilution with denatura- 
tion buffer according to the method of Bradford [5]. For calibration, HSA 
(50- 800 gg/ml) was dissolved in denaturation buffer. 
Stability determination 
The stability of the diastereoisomeric diaqua[1,2-bis(4-fluorophenyl)- 
ethylenediamine]platinum(II) sulfates (compounds I and II) and cisplatin 
in the presence of nucleophiles was evaluated according to the following 
experimental protocol: 
1. The platinum complexes (final concentration, 5 ~tM) were prein- 
cubated in culture medium (containing 10% FCS) for 1, 6, and 48 h 
under standard conditions (water-saturated atmosphere comprising 95% 
air/5% CO2 at 37 ~ C). 
2. The loss of activity against MCF-7 cells caused by preincubation 
was subsequently measured by the crystal viole*: chemosensitivity assay. 
Accumulation studies 
Drug treatment and sample preparation. FoI platinum-accumulation 
studies, cells (in passage 160) were grown in 175-cm z culture flasks 
(Falcon Plastics 3028). When the cells had approached confluency, the 
culture medium was aspirated and replaced with fresh medium contain- 
ing 5 gM platinum complex or 0.1% DMF (blank), whereby 50 gl feed 
solution was added to 50 ml culture medium. Four culture flasks were 
used for the blanks over 15-s, 15-rain, 30-rain, 45-rain, and 60-rain 
incubation periods, whereas three flasks were prepared for 2-, 4-, 12-, 
and 24-h drug exposure periods. Except for the blanks and the 15-s 
samples, which were processed immediately, all culture flasks were 
returned to the incubator. At appropriate time points, the flasks were 
removed from the incubator, the medium was aspirated, and the cells 
were thoroughiy washed twice with 10 ml 0.9% LiC1 solution. The cells 
were harvested after treatment with 3 ml 0.05% trypsin (ca. 1 rain, tryp- 
sin dissolved at 1:250, v/v, in 0.9% LiC1) in 5 ml 0.9% LiC1. For 
complete removal of the cells, the culture flasks were rinsed with an 
additional 5 ml 0.9% LiC1 solution. At each time point, the cells were 
pooled and centrifuged at 250 g for 15 rain. The pellet was resuspended 
in 10 ml 0.9% LiC1 and centrifugation was repeated. Finally, the washing 
solution was decanted from the cell pellet. Following vortexing, the 
homogeneous cell suspensions (ca. 800 gl) were split. About two-thirds 
of each cell suspension was transferred into quartz ampoules for plati- 
num and an aliquot was used for protein measurement. All samples were 
weighed. 
Platinum analysis. Platinum was determined by neutron-activation anal- 
ysis (NAA). Samples (300-600 mg cell suspension) were lyophilized in 
Correlation of ceil number and protein content. Cells were cultured and 
harvested by routine techniques. After three cycles of washing (PBS) and 
centrifugation, cells were suspended inPBS and various dilutions (n = 6) 
were prepared. Protein was measured as described above. In parallel, the 
cell number was determined using a hemocytometer by counting the 
nuclei remaining after lysis of the cells with 0.1% citric acid containing 
0.02% crystal violet. 
Determination of cell volume. The diameters of trypsinized MCF-7 cells 
(n = 50) were determined in culture medium using an Olympus BH-2 
microscope quipped with an SPlan 40 PL (phase-contrast) objective 
(Olympus Optical Co. Ltd., Tokyo, Japan). The microscopic image was 
focused through an NFK 2.5 • photoeyepiece to a Panasonic F10 CCD 
videocamera (Matsushita Communication I dustrial Co., Ltd., Osaka, 
Japan). For image analysis, the video signal was transformed in a PIP- 
512/1024A video digitizer board (Matrox Electronic Systems Ltd., Que- 
bec, Canada) installed in an Olivetti M24 personal computer (Ivrea, 
Italy) and then visualized on a Sony PVM-1371 QM video monitor 
(Tokyo, Japan). Cell diameters were marked using a mouse and then 
automatically measured by an image-processing program written in 
TURBO PASCAL. The volumes of 50 cells were calculated from the 
diameters, assuming a spherical cell shape. 
Calculation of cellular platinum concentration. The analysis of all cell 
suspensions provided the following data: the mass of the cell suspension 
used for NAA (mcsp,NAA), the platinum mass found in the NAA sample 
(mPt,csp,NAA), and the protein content of the cell suspension (Wp~t.osp). For 
calculations ofcell-associated platinum (cPt,c) on a molar basis, the value 
for the mean protein-mass concentration i the cells (/Sprt,C) must be 
known; pprt,c is defined as the mean protein mass per cell divided by the 
mean cell volume. The mean protein-mass concentration was determined 
in a separate xperiment as described above. Cell-associated platinum 
expressed inmoles per liter was calculated by the equation 
CPt,c = (mpt,csp,NAA/MPt) X ~prt, C/Wprt,csp X mcsp,NAA), (2) 
where Mvt represents he molar mass of platinum. 
DNA platination. MCF-7 cells (204th passage) were treated with 5 gM 
platinum complex as described above. At the time points indicated in 
Table 1, the cells from two 175-cm z flasks were pooled and the DNA was 
isolated according to the procedure described by Fichtinger-Schepman 
and collegues [9], including an additional high-salt step using 7.5 M 
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Fig. 2 A -D. Effect of drug concentration  cell proliferation following 
long-term incubation of MCF-7 cells (passage 155) with the platinum 
complexes shown in Fig. 1. [2, 0.5 gM; O, 1 gM; /X, 5 gM; A, 10 gM; 
0,  proliferation kinetics of the corresponding controls (absorbance at
578 nm). A Cisplatin. B Raceme-diaqua[1,2-bis(4-fluorophenyl)ethyl- 
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enediamine]platinum(II) sulfate (compound I). C Meso-diaqua[1,2- 
bis(4-fluorophenyl)ethylenediamine]platinum(II) sulfate (compound II). 
D Meso-diaqua[ 1,2-bis(2,6-dichJoro-4-hydroxyphenyl)ethylenediami- 
neplatinum(II) sulfate (compound III) 
Table 1. Kinetics of DNA platination during treatment of 204th-passage 
MCF-7 cells with 5 pm cisplatin and diaqua(1,2-diphenylethylenedi- 
amine)platinum(II) sulfates 
Time (h) Number of base pairs/platinum atom 
Compound 
Cisplatin I II III 
4 99,400 17,500 415,000 1,140,000 
12 65,200 19,900 77,700 343,000 
24 64,100 22,400 38,800 86,000 
ammonium acetate. The samples were prepared induplicate. DNA purity 
and concentration were determined by routine fluorescence and UV 
spectrophotometric methods [4]. DNA-associated platinum was mea- 
sured by NAA. 
Results 
Permanent drug exposure and chemosensitivity 
MCF-7 cells (in passage 155) were treated with com- 
pounds I - I I I  and cisplatin in three concentrations (0.5, 1, 
and 5 BM for compound I, compound II, and cisplatin, and 
1, 5, and 10 gu  for compound III) at 48 h after seeding. In 
this experiment, he drug- (and vehicle-) containing culture 
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Fig. 3 A- C. Effect of preincubation with cisplatin and diastereoisomeric 
diaqua[ 1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II) sulfates on 
inhibition of the proliferation fMCF-7 (passage 183) breast cancer 
cells. Prior to the routine chemosensitivity assay, the platinum complexes 
(5 gM) were incubated with culture medium containing 10% FCS. D, No 
preincubation; O, 1 h preincubation; O, 6 h preincubation; I ,  48 h 
preincubation. A Cisplatin. B Raceme-diaqua[1,2-bis(4-fluorophenyl)- 
ethylenediamine]platinum(II) sulfate (compound I). C Meso-diaqua[ 1,2- 
bis(4-fluorophenyl)ethylenediamine]platinum(II) sulfate (compound II) 
media were left unchanged throughout the incubation peri- 
od. The results are summarized in Fig. 2. In these plots of 
T/Ccorr vs time of incubation, time zero indicates the time 
at which drug was added. According to Eq. 1, any growth 
curve for a drug-treated cell population can be recon- 
structed from the T/Ccorr values and the growth-curve data 
of the corresponding control [2]. 
For compounds I and II and cisplatin, a clear-cut dose- 
dependent inhibition of cell proliferation that resulted in 
final equiactivity at 5 gM was observed, whereas com- 
pound III was ineffective at 1 and 5 gM. Even at a very high 
dose (10 gM), compound III produced only weak, transient 
effects, i.e., the culture recovered and regained complete 
reproductive integrity. The extent of dose dependence 
decreased from coumpound II (flat dose-response relation- 
ship) to compound I to cisplatin (steep dose-resPonse r la- 
tionship) and was paralMed by an increase in antiprolifera- 
tive activity for the 0.5- and 1-gM doses. At the highest 
concentration (5 gM), all three platinum complexes pro- 
duced T/Ccorr values of zero (i. e., 100% inhibition of net 
cell proliferation) toward the end of the incubation period. 
Surprisingly, in comparison with the activity of its meso- 
configurated counterpart (compound II), the onset of ac- 
tion of the racemic omplex (compound I) was considera- 
bly faster. 
Stability of cisplatin, raceme-, and meso-diaqua[1,2- 
bis( 4-fluorophenyI )ethylenediamine ]platinum( II) sulfate 
in culture medium 
For all complexes, a complete loss of activity was observed 
after 48 h preincubation (Fig. 3) due to inactivation 
processes resulting from reactions with nucleophiles such 
as amino acids and serum proteins. Whereas cisplatin dis- 
played full activity after 6 h preincubation, compounds I 
and II showed considerable inactivation. Within the range 
of experimental error, there was no difference in the reac- 
tivities of the diastereoisomers. 
Short-term drug exposure and chemosensitivity 
To determine the duration of drug exposure required to 
achieve optimal inhibitory effects, MCF-7 cells were incu- 
bated in the presence of 5 gM cisplatin, compound I, and 
compound II for 4, 6, and 12 h. After the indicated periods 
of drug exposure, the platinum complexes were removed 
by medium exchange and the T/Ccorr values were deter- 
mined at various times during incubation of the cultures in 
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Fig. 4 A -C .  Effect of the duration of drug exposure on the proliferation 
of MCF-7 cells (passage 194). First, the cells were incubated for 4 ( 9 ), 
6 (O), and 12 h (  9  in the presence of 5 ~tM platinum complex; then, the 
drug-containing media were replaced by fresh drug-free culture medium 
(t = 0) and the cells were incubated under standard conditions for 231 h. 
F], Permanent incubation of the cells in the presence of drug (231 h). 
A Cisplatin. B Raceme-diaqua[1,2-bis(4-fluorophenyl)ethylenediami- 
ne]platinum(II) sulfate (compound I). C Meso-diaqua[1,2-bis(4- 
fluorophenyl)ethylenediamine]platinum(II) s lfate (compound II) 
fresh medium. Figure 4 shows direct proportionality for 
the duration of drug exposure and the inhibition of cell 
proliferation. All three platinum complexes displayed 
maximal activity after 12 h. It is noteworthy that after 6 h 
incubation, compound I and cisplatin produced compara- 
ble T/Ccorr values (around 20%), although compound I was 
definitely less stable in culture medium (cf. Fig. 3). In 
contrast, 12 h drug exposure was necessary for its meso- 
configurated counterpart (compound II) to become quiac- 
rive at the given concentration. In addition, the manifesta- 
tion of cytotoxicity was markedly faster for compound I 
than for cisplatin or compound II. 
Platinum accumulation by MCF-7 cells 
For estimations of cell-associated platinum on a molar 
basis, the following parameters were determined in a sepa- 
rate experiment. The mean diameter of the cells suspended 
in culture medium was 16.2+ 3.0 gm. The volumes of 50 
cells were calculated from the corresponding cell diame- 
ters: the mean cell volume was 2.46 + 1.61 pl. The mean 
protein mass per cell was 0.205+0.021 ng. These data 
yielded a mean protein-mass concentration i the cell of 
83.5 + 55.5 g 1-1. 
MCF-7 (passage 160) cells were incubated with 5 gM 
compounds I-I I I  and cisplatin. Figure 5 illustrates the 
kinetics of platinum accumulation by MCF-7 cells. After 
15 s drug exposure, no platinum was associated with the 
cells. In contrast to compound III and cisplatin, in the case 
of the diastereoisomers (compounds I and II), platinum 
was selectively accumulated with high specificity. For the 
racemate (compound I), accumulation was very rapid, with 
an intracellular platinum concentration of 68 gmol 1-1 
being reached within 4 h. The platinum concentration for 
meso-configurated compound II amounted to 15 gmol 1-1, 
whereas that for both the meso-configurated compound III 
(3.3 gmoll-1) and cisplatin (2.1 I, tmol 1-1) were signifi- 
cantly lower. Although at the end of the experiment, he 
amount of cell-associated platinum resulting from treat- 
ment of the cells with compound III was lower than that 
9 resulting for incubation with cisplatin, the initial accumula- 
tion of platinum by the cells was faster following incuba- 
tion with compound III (cf. Fig. 5 B). 
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Fig. 5 A, B. Platinum accumulation byMCF-7 ceils (passage 160), The 
cultures were treated with 5 gM platinum complex in MEM Eagle's 
medium containing 10% FCS. Platinum accumulation is shown on the 
basis of the mean intracellular concentration expressed in gmol 1 -I. A A, 
Raceme-diaqua[ 1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II) 
sulfate (compound I); A, meso-diaqua[1,2-bis(4-fluorophenyl)ethylene- 
diamine]platinum(II) sulfate (compound II); [], meso-diaqua[1,2- 
bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]platinum(II) sulfate 
(compound III); O, cisplatin. B Comparison ofinitial platinum accumu- 
lation after treatment with meso-diaqua[ 1,2-bis(2,6-dichloro-4-hydroxy- 
phenyl)ethylenediamine]platinum(II) s lfate (compound III, [] ) and cis- 
platin (O) 
DNA platination 
To understand the missing overall difference in the cyto- 
toxicity of cisplatin vs compound I (ahhough the latter was 
strongly accumulated), we determined the platinum con- 
tent of DNA after the exposure of MCF-7 cells to each of 
the four complexes. In Table 1, the results of this experi- 
ment are summarized as mean values for the number of 
base pairs per platinum atom. The base pair/platinum ratios 
after 4 h exposure were 17,500 for compound I (high de- 
gree of platination), 415,000 for compound II, 99,400 for 
cisplatin, and 1,140,000 for compound III (low degree of 
platination). In contrast to all of the other complexes, for 
which the extent of DNA platination increased with time, 
the reaction of compound I with DNA was quite rapid (i. e., 
the degree of platination was maximal after 4 h). Surpris- 
ingly, after 24 h, only a 1.3-fold difference in DNA-as- 
sociated platinum was found for cisplatin vs compound III, 
although the latter was ineffective (cf. Fig. 2) and was not 
accumulated by the cells (see Fig. 5). 
Discussion 
The present study revealed vast differences in the activity 
of the investigated stereoisomeric diaqua(1,2-diphenyl- 
ethylenediamine)platinum(II) sulfates and cisplatin against 
the estrogen-receptor-positive human MCF-7 breast- 
cancer cell line. Wheres compound I, compound II, and 
cisplatin inhibited cell proliferation in a dose-dependent 
manner, compound III was ineffective at even an ex- 
tremely high (10 gmol 1-1) dose following long-term drug 
exposure (231 h). This observation contrasts with the re- 
sults of previous tudies, in which this estrogenic platinum 
complex displayed selective and highly reproducible inhi- 
bition of estrogen-receptor-positive, ovarian-dependent ro- 
dent breast cancers [14, 29]. Cisplatin and both of the 
diastereoisomeric diaqua[ 1,2-bis(4-fluorophenyl)ethyl- 
enediamine]platinum(II) sulfates (compounds I and II) 
were equiactive at the 5-gM concentration (Fig. 2), al- 
though their onset of action differed. A maximal effect 
(T/Ccorr values of around zero) was observed for the race- 
mate (compound I) after about 90 h, for cisplatin after 
about 200 h, and for the meso-configurated compound II
after more than 230 h incubation. 
This phenomenon could be ascribed to a variation of the 
extent or rate of inactivation of the drugs resulting from 
reactions with nucleophiles (e.g., amino acids or serum 
proteins) in the culture medium. It should be borne in mind 
that in experiments involving prolonged drug-exposure 
periods, the theoretical concentration-time product (c x t 
value) is equal to the actual c x t value only if the drugs 
retain their full activity at 37~ over the entire exposure 
period and the response is linear with time. Differences in 
reactivity would cause different levels of effective concen- 
tration during the course of the chemosensitivity assay. In 
analogy to the pharmacokinetic principle of the equieffec- 
tiveness of equal areas under the curve, identical 
c x t values are a prerequisite for intrinsically equiactive 
drugs. Therefore, a decrease in activity due to a lowered 
effective concentration would be compensated bya prolon- 
gation of the exposure period. 
To test his hypothesis, cisplatin and compounds I and II 
were preincubated with culture medium for various inter- 
vals under standard conditions (Fig. 3). After 6 h incuba- 
tion in medium, cisplatin was fully active, whereas a 
complete loss of activity was observed after 48 h incuba- 
tion in medium containing 10% FCS. These findings are 
consistent with stability data for cisplatin described in the 
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literature [35]. In comparison with cisplatin, the inactiva- 
tion of diastereoisomers I and II was faster, with a loss of 
about 30% of their inhibitory activity being observed after 
6 h preincubation. Although it is possible that a chloride 
ligand in cisplatin might in some cases be directly dis- 
placed through a reaction with a macromolecule, it is 
generally agreed that the more common pathway involves 
an initial aquation reaction in which a chloride is replaced 
by a water molecule [22]. In water, the equilibrium con- 
stant of the first aquation reaction is 4.4 mM at a tempera- 
ture of 37 ~ C and a tl/2 value of 2.5 h. These values indicate 
that for 4.4 mM cisplatin in water, an equilibrium ratio of 
1:1 for the dichloro:chloroaquo species is eventually 
reached after 2.5 h. Because of the slowness of this reac- 
tion and the presence of reactive constituents other than 
water, it is highly unlikely that equilibrium would be ap- 
proached in biological fluids [22]. In blood plasma and in 
culture medium, the high chloride concentration keeps cis- 
platin predominantly in the uncharged and relatively non- 
reactive dichloro form, which guarantees its stability for at 
least 6 h (cf. Fig. 3 A). Inactivation of the highly reactive 
diaqua[1,2-bis(4-fluorophenyl) thylenediamine]platinum 
(II) sulfates through reactions with medium components is 
obvious, since no aquation step is required. However, in 
terms of reactivity, diastereoisomeric compounds I and II 
were identical. Therefore, inactivation processes cannot 
explain the striking difference in the manifestation ofdrug 
action (Fig. 2 B, C). 
Because of the relatively fast inactivation of compounds 
I and II, the lesions that eventually cause inhibition of cell 
proliferation and cell death would have to arise within the 
first few hours of the chemosensitivity assay. To test this 
hypothesis, the antitumor activity of cisplatin, compound I, 
and compound II was compared as a function of the dura- 
tion of drug exposure. Figure 4 illustrates that all of the 
platinum complexes produced a gradual decrease inT/Ccorr 
values with increasing time of drug exposure, and a maxi- 
mal effect (i. e., the same as that observed after permanent 
drug exposure for 231 h) was observed as early as after 
about 12 h. It is surprising that cisplatin and the racemate 
(compound I) were equiactive when the cells were treated 
for 6 h, despite the relative instability of compound I in 
culture medium. Since there was no difference in the reac- 
tivity of the diastereoisomeric counterparts (compounds I 
and II), the delayed manifestation f the action of complex 
II is not likely to originate from a lower platination rate of 
the target molecule DNA due to steric hindrance of the 
meso-configurated compound II (cf. Fig. 1), as has pre- 
viously been assumed [241. 
In this context, penetration of the platinum complexes 
into the tumor cell seemed to be a critical factor. The 
above-described quilibrium reaction of cisplatin may be 
of pharmacological importance not only because of the 
high reactivity of the aquated species but also due to the 
different ionic states that may affect the drug's ability to 
penetrate lipid membranes [22]. The uncharged species, 
including the dichloro and chlorohydroxy complexes, 
would be expected to enter the cell by passive diffusion 
[10, 21]. Nevertheless, conflicting reports have appeared in
the literature regarding the mechanism of cisplatin uptake 
[1]. Byfield and Calabro-Jones [8] reported that cisplatin 
uptake may be carrier-mediated, but this evidence was 
indirect. It has also been suggested that cisplatin may be 
transported into the kidney by the organic ation-transport 
system [26, 34]. A specific uptake of the positively charged 
compounds I and II by similar carrier mechanisms could 
explain the differences observed in the antitumor activity 
of the diastereoisomers due to their stereochemical harac- 
teristics. 
Comparative uptake studies (Fig. 5) using cisplatin and 
compounds I-I I I  revealed vast differences in platinum 
accumulation. We found that no measurable platinum was 
associated with MCF-7 cells after the platinum complexes 
had been removed at 15 s following their addition to the 
culture flasks, indicating alack of immediate surface bind- 
ing of the drugs to these cells. A kinetic investigation ofthe 
reaction of the diastereoisomeric compounds I and II 
(3 gM) with 3.4 mg human serum albumirdml buffer (con- 
centrations comparable to the situation in the uptake ex- 
periments) revealed that both compounds bound avidly to 
serum protein within the 1st hour (data not shown). Due to 
the great excess of serum proteins as compared with cellu- 
lar surface protein and to the identical reactivity of the 
diaqua(1,2-diphenylethylenediamine)platinum(II) com- 
plexes I and II, surface reactions are highly unlikely, al- 
though from these studies one cannot distinguish between 
binding of the drugs to cell-surface components and true 
uptake. 
For the diastereoisomeric compounds I and II, platinum 
accumulation was high as compared with that found for 
both the meso-configurated platinum complex III and cis- 
platin. In the case of compound I, the platinum associated 
with MCF-7 cells amounted to about 93 gM (cf. Fig. 5 A). 
The platinum uptake for compound I was highly specific 
and faster than that observed for its meso-configurated 
counterpart compound II. This discrepancy between the 
diastereoisomers supports the supposition that the uptake 
of the diastereoisomeric diaqua[1,2-bis(4-fiuorophenyl)- 
ethylenediamine]platinum(II) sulfates by MCF-7 cells is 
carrier-mediated. The plateau of the platinum-uptake 
curves after prolonged incubation could be explained by 
damage of the carrier protein as a result of platination. The 
specificity seems to be coupled to the three-dimensional 
structure of the 1,2-bis(4-fluorophenyl)ethylenediamine 
ligand, since the cellular accumulation of the structurally 
closely related platinum complex III (cf. Fig. 1) was rather 
poor. However, in comparison with cisplatin, the platinum 
accumulation found for compound III was initially faster 
(see Fig. 5 B), which may reflect different mechanisms of 
uptake. 
Although the differences observed in the onset of inhi- 
bition of cell proliferation by the cisplatin analogues could 
partly be explained by different platinum-accumulation 
velocities, cytotoxicity was not directly correlated with 
platinum uptake. On the one hand, the low capacity of the 
estrogen-receptor-positive MCF-7 cell line for the accu- 
mulation of meso-diaqua[ 1,2-bis(2,6-dichloro-4-hydroxy- 
phenyl)ethylenediamine]platinum(II) sulfate (compound 
III) would be consistent with the ineffectiveness of this 
compound, and on the other, cisplatin and the dia- 
stereoisomeric complexes I and II exhibited equiactivity 
despite the striking differences observed in the cellular 
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association of platinum resulting from the incubation of 
cells with these compounds (cf. Fig. 5 A). 
In addition, the differences in antimmor activity are not 
completely explainable by the degree of DNA platination 
caused by the particular compound (see Table 1). Early 
events in DNA platination seem to produce the critical 
lesions (intra- or interstrand cross-links), finally resulting 
in lethal damage. Although we have recently demonstrated 
that in a solution containing sulfate as the only anion [15], 
positively charged platinum complexes are accumulated 
by breast cancer cells, the identification of the species 
transported in complex media and investigations relating 
the mechanism of drug uptake and DNA platination to 
DNA repair should give us a more thorough understanding 
of this multifaceted phenomenon. Provided that effective 
plasma levels can be maintained for about 6 h, raceme- 
diaqua[ t,2-bis(4-fluorophenyl)ethylenediamine]platinum- 
(II) sulfate (compound I) should be superior to cisplatin in 
the treatment ofhuman MCF-7 breast umors transplanted 
into nude mice. 
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